María Luz Martínez-Chantar Liver Disease and Liver Metabolism Lab CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd) Biography Publications Institution JoVE Articles María Luz Martínez-Chantar has not added a biography. If you are María Luz Martínez-Chantar and would like to personalize this page please email our Author Liaison for assistance. Publications SUMOylation Regulates LKB1 Localization and Its Oncogenic Activity in Liver Cancer EBioMedicine. Feb, 2019 | Pubmed ID: 30594553 MiR-873-5p Acts As an Epigenetic Regulator in Early Stages of Liver Fibrosis and Cirrhosis Cell Death & Disease. 09, 2018 | Pubmed ID: 30237481 The Mitochondrial Negative Regulator MCJ is a Therapeutic Target for Acetaminophen-induced Liver Injury Nature Communications. 12, 2017 | Pubmed ID: 29233977 Methionine and S-adenosylmethionine Levels Are Critical Regulators of PP2A Activity Modulating Lipophagy During Steatosis Journal of Hepatology. Feb, 2016 | Pubmed ID: 26394163 NEDDylation in Liver Cancer: The Regulation of the RNA Binding Protein Hu Antigen R Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]. Jul, 2015 | Pubmed ID: 25841271 Hepatoma Cells from Mice Deficient in Glycine N-methyltransferase Have Increased RAS Signaling and Activation of Liver Kinase B1 Gastroenterology. Sep, 2012 | Pubmed ID: 22687285 Activation of LKB1-Akt Pathway Independent of Phosphoinositide 3-kinase Plays a Critical Role in the Proliferation of Hepatocellular Carcinoma from Nonalcoholic Steatohepatitis Hepatology (Baltimore, Md.). Nov, 2010 | Pubmed ID: 20815019 SumO-Binding Entities (SUBEs) comme outils pour l'enrichissement, l'isolement, l'identification et la caractérisation du protéome SUMO dans le cancer du foie Fernando Lopitz-Otsoa1, Teresa C Delgado1, Sofía Lachiondo-Ortega1, Mikel Azkargorta2, Felix Elortza2, Manuel S Rodríguez3, María Luz Martínez-Chantar1 1Liver Disease and Liver Metabolism Lab, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 2Proteomics Platforms, CIC bioGUNE, ProteoRED-ISCIII, CIBERehd, 3Advanced Technology Institute in Life Sciences (ITAV)-CNRS-IPBS, UbiCARE JoVE 60098 Biochemistry
SumO-Binding Entities (SUBEs) comme outils pour l'enrichissement, l'isolement, l'identification et la caractérisation du protéome SUMO dans le cancer du foie Fernando Lopitz-Otsoa1, Teresa C Delgado1, Sofía Lachiondo-Ortega1, Mikel Azkargorta2, Felix Elortza2, Manuel S Rodríguez3, María Luz Martínez-Chantar1 1Liver Disease and Liver Metabolism Lab, CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 2Proteomics Platforms, CIC bioGUNE, ProteoRED-ISCIII, CIBERehd, 3Advanced Technology Institute in Life Sciences (ITAV)-CNRS-IPBS, UbiCARE JoVE 60098 Biochemistry
